Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti P M, Ewer K J, Aley P K, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck E A, Dold C, Faust S N, Finn A, Flaxman A L, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian A M, Pollock K M, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas A D, Hill A V S, Lambe T, Gilbert S C, Pollard A J, on behalf of Oxford COVID Vaccine Trial Group